‘More applications beyond PE’: Cyclopharm innovates in asthma research space

Cyclopharm Chief Executive James McBrayer explains how the company is expanding into the asthma research space.

“We’re mostly known for diagnosing pulmonary embolism (PE),” Mr McBrayer told Sky News Australia.

“In the 66 countries in which we operate, that’s what we’re best known for; however, because we’re a true functional ventilation imaging agent, we’re seeing more applications beyond PE.”